Loading...
XNYS
IQV
Market cap27bUSD
Jun 10, Last price  
159.77USD
1D
3.65%
1Q
-13.83%
Jan 2017
110.09%
IPO
276.90%
Name

IQVIA Holdings Inc

Chart & Performance

D1W1MN
P/E
20.13
P/S
1.79
EPS
7.94
Div Yield, %
—
Shrs. gr., 5y
-1.68%
Rev. gr., 5y
6.80%
Revenues
15.41b
+2.81%
3,924,020,0004,327,748,0004,865,513,0005,099,545,0005,459,998,0005,737,619,0006,878,000,0009,739,000,00010,412,000,00011,088,000,00011,359,000,00013,874,000,00014,410,000,00014,984,000,00015,405,000,000
Net income
1.37b
+1.10%
160,596,000241,772,000177,546,000226,591,000356,383,000387,205,000115,000,0001,309,000,000259,000,000191,000,000279,000,000966,000,0001,091,000,0001,358,000,0001,373,000,000
CFO
2.72b
+26.38%
378,160,000160,953,000335,701,000397,370,000431,754,000475,691,000860,000,000970,000,0001,254,000,0001,417,000,0001,959,000,0002,942,000,0002,260,000,0002,149,000,0002,716,000,000
Earnings
Jul 21, 2025

Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
URL
https://ir.iqvia.com/
IPO date
May 09, 2013
Employees
87,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
15,405,000
2.81%
14,984,000
3.98%
14,410,000
3.86%
Cost of revenue
10,030,000
9,745,000
9,382,000
Unusual Expense (Income)
NOPBT
5,375,000
5,239,000
5,028,000
NOPBT Margin
34.89%
34.96%
34.89%
Operating Taxes
301,000
101,000
260,000
Tax Rate
5.60%
1.93%
5.17%
NOPAT
5,074,000
5,138,000
4,768,000
Net income
1,373,000
1.10%
1,358,000
24.47%
1,091,000
12.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,350,000)
(992,000)
(1,168,000)
BB yield
3.75%
2.30%
2.99%
Debt
Debt current
1,145,000
825,000
152,000
Long-term debt
519,000
13,857,000
13,123,000
Deferred revenue
464,000
Other long-term liabilities
13,333,000
470,000
207,000
Net debt
(146,000)
12,947,000
11,804,000
Cash flow
Cash from operating activities
2,716,000
2,149,000
2,260,000
CAPEX
(649,000)
(674,000)
Cash from investing activities
(1,444,000)
(1,603,000)
(2,006,000)
Cash from financing activities
(878,000)
(382,000)
(329,000)
FCF
5,120,000
4,737,000
4,866,000
Balance
Cash
1,702,000
1,496,000
1,309,000
Long term investments
108,000
239,000
162,000
Excess cash
1,039,750
985,800
750,500
Stockholders' equity
16,170,000
3,828,000
13,505,000
Invested Capital
19,851,250
19,827,200
18,535,500
ROIC
25.58%
26.79%
26.07%
ROCE
25.49%
24.93%
25.46%
EV
Common stock shares outstanding
183,400
186,300
190,600
Price
196.51
-15.07%
231.38
12.93%
204.89
-27.38%
Market cap
36,039,934
-16.39%
43,106,094
10.38%
39,052,034
-29.02%
EV
35,893,934
56,053,094
50,856,034
EBITDA
6,489,000
6,364,000
6,158,000
EV/EBITDA
5.53
8.81
8.26
Interest
670,000
672,000
416,000
Interest/NOPBT
12.47%
12.83%
8.27%